Neurion Pharmaceuticals

Neurion Pharmaceuticals was a biotechnology company focused on the discovery of small molecule therapeutics targeting ion channels for the treatment of central nervous system disorders and chronic pain. The company's core technology was the Precision Ion Channel Discovery (PICD) platform, which enabled high-throughput screening and precise characterization of ion channel modulators. This platform was designed to overcome the traditional challenges of selectivity and potency in ion channel drug discovery. Neurion's research efforts targeted various classes of ion channels, including sodium, potassium, and calcium channels, as well as ligand-gated channels like GABA-A receptors. In October 2006, Neurion was acquired by Neurogen Corporation, integrating its technology and expertise into Neurogen's broader CNS pipeline.